Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1703||SWOG||Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer||Cancer Prevention and Control CIRB||Available to Open|
|S1706||SWOG||A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1712||SWOG||A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1714||SWOG||A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients||Cancer Prevention and Control CIRB||Available to Open|
|S1800A||SWOG||A Phase II Randomized Study of Ramucirumab plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1801||SWOG||A Phase II Randomized Study of Adjuvant versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Sage III-IV High Risk Melanoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1802||SWOG||Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1803||SWOG||Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC STUDY)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1806||SWOG||Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1815||SWOG||A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers||Adult CIRB - Late Phase Emphasis||Available to Open|